• Over 25 years of executive management in the life science industry; President of Cardioresponse, VP Coordinated Care Solutions, Managing Partner of Extera, Managing Director & Head Life Sciences at Armory Securities, Board Member of Janus Biotherapeutics, Atacama Therapeutics & Acer Therapeutics, and multiple corporate development roles with small to midsize life science companies. Jonathan earned his MD from the Technion Institute of Technology and his MBA from the Harvard Business School.

  • Neil has broad expertise in drug development, functional areas of business development, project management, regulatory affairs, and clinical project management and operations. As a Senior Director of External Innovation at Eli Lilly and Company, Neil was focused on venture capital backed investments into new company creation of project focused companies. Neil also held direct responsibilities for regulatory filings with major competent authorities globally, and for the design and oversight of early phase drug development programs, including phase 1 first-in-man clinical trials as part of Chorus, Eli Lilly’s virtual drug development engine. Prior to his current role at Censa, he was a Senior Director Project Management and Head BD with Flexion Therapeutics. Neil has a Doctor of Pharmacy degree from the University of Maryland Baltimore and a Master in Business Administration from the University of Baltimore.

  • dlevybw

    Daniel has 25 years of experience leading chemistry research and development programs.  He was the Director of Synthetic Chemistry at Intradigm and a Medicinal Chemistry Group Leader at Scios.  He is the founder of DEL BioPharma LLC providing cost-effective strategies supporting chemical research and manufacturing projects.  Daniel received his PhD in organic chemistry from MIT and his BS in chemistry from the University of California – Berkeley.  

  • Jeff has 25+ years of business and corporate development expertise; led or supported over 30 transactions with an aggregate value in excess of $1B across all major therapeutic platforms. Has orphan drug expertise. Currently a Partner at Extera Partners. Previously at Genzyme, Archemix, ImmunoGen, GenVec, and Eli Lilly.

  • Pam has extensive global regulatory affairs leadership experience ,including a strong track record in rare diseases. Her background spans multiple therapeutic areas, with successful worldwide registrations including both biologics and small molecules. She also has broad expertise in the areas of quality assurance, manufacturing operations, pharmacovigilance and health authority compliance. She is the former Senior Vice President, Global Regulatory Affairs & Patient Safety of Alexion Pharmaceuticals, the former SVP, Global Head, Regulatory Affairs and Compliance at Genzyme Corporation and the former VP of Regulatory Affairs and Quality Assurance at Serono. Pam holds a Master’s degree in Business Administration from Northeastern University and a Bachelor’s Degree in Psychology from Skidmore College. Pam is also Regulatory Affairs Certified, has the distinction of being a Regulatory Affairs Professional Society Fellow and is a member of the Albany College of Pharmacy & Health Sciences Board of Trustees.